| P2093 | author name string | Chris Orvig | |
| | Eric W Price | |
| P2860 | cites work | Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides | Q24649091 |
| | Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides | Q25939007 |
| | The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals | Q26849599 |
| | Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability | Q27339846 |
| | Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET | Q28487987 |
| | Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts | Q28535054 |
| | Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA | Q28741667 |
| | Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase | Q29619948 |
| | Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data | Q30666654 |
| | Lanthanide chelates containing pyridine units with potential application as contrast agents in magnetic resonance imaging | Q30943863 |
| | The highest water exchange rate ever measured for a Gd(III) chelate | Q31006037 |
| | Pyridine- and phosphonate-containing ligands for stable Ln complexation. Extremely fast water exchange on the Gd(III) chelates | Q31065362 |
| | Lanthanide complexes based on a 1,7-diaza-12-crown-4 platform containing picolinate pendants: a new structural entry for the design of magnetic resonance imaging contrast agents. | Q31167267 |
| | Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. | Q33301860 |
| | Synthesis and evaluation of novel polyaminocarboxylate-based antitumor agents | Q33324145 |
| | Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab | Q33527397 |
| | p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging | Q33629386 |
| | Non-cross-bridged tetraazamacrocyclic chelator for stable (64)cu-based radiopharmaceuticals | Q33636030 |
| | Standardized methods for the production of high specific-activity zirconium-89. | Q33685309 |
| | Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects | Q33708506 |
| | HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts | Q33862523 |
| | Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent | Q33867187 |
| | Improved in vivo stability of actinium-225 macrocyclic complexes | Q33869349 |
| | Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease | Q33870879 |
| | In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. | Q33909857 |
| | PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab. | Q33939881 |
| | Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma | Q33943630 |
| | Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. | Q39506156 |
| | PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference | Q39523102 |
| | Efficient synthesis and evaluation of bimodal ligand NETA. | Q46620038 |
| | Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature | Q46801081 |
| | 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model | Q46934969 |
| | Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial | Q48306398 |
| | [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation | Q48830083 |
| | Indium (III) and gallium (III) complexes of bis(aminoethanethiol) ligands with different denticities: stabilities, molecular modeling, and in vivo behavior | Q49161853 |
| | Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃. | Q53140894 |
| | New Ga derivatives of the H2dedpa scaffold with improved clearance and persistent heart uptake. | Q53208611 |
| | Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. | Q53384826 |
| | Revival of TE2A; a better chelate for Cu(II) ions than TETA? | Q53466758 |
| | Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). | Q53493051 |
| | New 64Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr. | Q53517111 |
| | Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. | Q53529879 |
| | Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide. | Q53530705 |
| | Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. | Q53543032 |
| | Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). | Q54744326 |
| | Synthesis of novel 1,3,5-cis,cis-triaminocyclohexane ligand based Cu(II) complexes as potential radiopharmaceuticals and correlation of structure and serum stability | Q57087314 |
| | Preparation of the Novel Chelating AgentN-(2-Aminoethyl)-trans-1,2-diaminocyclohexane-N,N‘,N‘‘-pentaacetic Acid (H5CyDTPA), a Preorganized Analogue of Diethylenetriaminepentaacetic Acid (H5DTPA), and the Structures of BiIII(CyDTPA)2-and BiIII(H | Q57087495 |
| | 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT | Q57757715 |
| | Mechanism and Energetics for Complexation of90Y with 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA), a Model for Cancer Radioimmunotherapy | Q58473551 |
| | A comparative study of aluminum(III), gallium(III), indium(III), and thallium(III) binding to human serum transferrin | Q58859008 |
| | Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era. | Q34111790 |
| | Complexation of metal ions with TRAP (1,4,7-triazacyclononane phosphinic acid) ligands and 1,4,7-triazacyclononane-1,4,7-triacetic acid: phosphinate-containing ligands as unique chelators for trivalent gallium. | Q34119384 |
| | PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab. | Q34126406 |
| | Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals | Q34136549 |
| | Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands | Q34160678 |
| | (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives | Q34188331 |
| | Bioorthogonal reaction pairs enable simultaneous, selective, multi-target imaging | Q34240233 |
| | Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression | Q34331845 |
| | 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. | Q34389457 |
| | The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications | Q34440633 |
| | Novel chelating agents for potential clinical applications of copper | Q34489850 |
| | Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma | Q34528384 |
| | Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. | Q34555716 |
| | Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents | Q34622747 |
| | In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer | Q34942281 |
| | Towards translation of 212Pb as a clinical therapeutic; getting the lead in! | Q35028126 |
| | Synthesis of target-specific radiolabeled peptides for diagnostic imaging | Q35044474 |
| | Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications | Q35098222 |
| | In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation | Q35204647 |
| | Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry | Q35394166 |
| | The next generation of positron emission tomography radiopharmaceuticals in oncology. | Q35525690 |
| | Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes. | Q35565660 |
| | Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. | Q35587248 |
| | Reproducibility of quantitative (R)-[11C]verapamil studies | Q35742284 |
| | 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET | Q36085489 |
| | [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study | Q36125639 |
| | Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy | Q36247600 |
| | Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms | Q36291655 |
| | PET imaging with ⁸⁹Zr: from radiochemistry to the clinic | Q36454584 |
| | Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. | Q36580750 |
| | Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. | Q36674828 |
| | Copper chelation chemistry and its role in copper radiopharmaceuticals. | Q36724065 |
| | Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI. | Q36813571 |
| | Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling. | Q36826058 |
| | Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. | Q39590473 |
| | ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature | Q39706929 |
| | Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system | Q39769801 |
| | The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy. | Q39853390 |
| | In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. | Q40107068 |
| | In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems | Q40107074 |
| | Nuclear uptake and dosimetry of 64Cu-labeled chelator somatostatin conjugates in an SSTr2-transfected human tumor cell line. | Q40107091 |
| | Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. | Q40365959 |
| | Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal | Q40426685 |
| | Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. | Q40435678 |
| | Conjugation of DOTA using isolated phenolic active esters: the labeling and biodistribution of albumin as blood pool marker. | Q40453707 |
| | Preclinical characterisation of 111In-DTPA-trastuzumab. | Q40491931 |
| | Stability of (47)Sc-complexes with acyclic polyamino-polycarboxylate ligands. | Q40679525 |
| | Search of ligands suitable for (212)Pb/(212)Bi in vivo generators. | Q40679548 |
| | Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides | Q40800753 |
| | Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction | Q40858096 |
| | Copper radionuclides and radiopharmaceuticals in nuclear medicine | Q40921172 |
| | Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications | Q41607195 |
| | Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga | Q41997142 |
| | THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience | Q42068740 |
| | A triazacyclononane-based bifunctional phosphinate ligand for the preparation of multimeric 68Ga tracers for positron emission tomography. | Q42167262 |
| | 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. | Q42626389 |
| | Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation. | Q42825863 |
| | Gallium(III) complexes of DOTA and DOTA-monoamide: kinetic and thermodynamic studies. | Q42837828 |
| | Acyclic chelate with ideal properties for (68)Ga PET imaging agent elaboration | Q42854505 |
| | Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine | Q43111522 |
| | Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. | Q43116972 |
| | Eight-coordinate Zn(II), Cd(II), and Pb(II) complexes based on a 1,7-diaza-12-crown-4 platform endowed with a remarkable selectivity over Ca(II). | Q43242815 |
| | Selective chelation of Cd(II) and Pb(II) versus Ca(II) and Zn(II) by using octadentate ligands containing pyridinecarboxylate and pyridyl pendants | Q43251889 |
| | Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo | Q43502823 |
| | Development of an in vitro model for assessing the in vivo stability of lanthanide chelates | Q43570130 |
| | A cyclen-based tetraphosphinate chelator for the preparation of radiolabeled tetrameric bioconjugates. | Q43595161 |
| | In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates | Q43625800 |
| | Synthesis and characterization of two (111)In-labeled DTPA-peptide conjugates | Q43679714 |
| | Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. | Q43849736 |
| | Conjugation of monoclonal antibodies with TETA using activated esters: biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3. | Q43853239 |
| | NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors | Q43992775 |
| | In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications | Q44007089 |
| | Comparison of yttrium and indium complexes of DOTA-BA and DOTA-MBA: models for (90)Y- and (111)In-labeled DOTA-biomolecule conjugates | Q44066333 |
| | Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics | Q44078080 |
| | Equilibrium and kinetic properties of the lanthanoids(III) and various divalent metal complexes of the heptadentate ligand AAZTA. | Q44295594 |
| | Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities | Q44391489 |
| | Isotachophoretic determination of stability constants of Ho and Y complexes with diethylenetriaminepentaacetic acid and 1,4,7,10-tetraazadodecane-N,N',N'',N'''-tetraacetic acid | Q44397038 |
| | Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins | Q44538103 |
| | Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent | Q44572339 |
| | Synthesis, characterization, and X-ray crystal structure of In(DOTA-AA) (AA = p-aminoanilide): a model for 111In-labeled DOTA-biomolecule conjugates | Q44700200 |
| | Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. | Q44784872 |
| | Synthesis of hexa aza cages, SarAr-NCS and AmBaSar and a study of their metal complexation, conjugation to nanomaterials and proteins for application in radioimaging and therapy | Q44934054 |
| | Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging | Q44944204 |
| | 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression | Q45399826 |
| | Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network. | Q45748256 |
| | Hexadentate bispidine derivatives as versatile bifunctional chelate agents for copper(II) radioisotopes | Q46144326 |
| | Zn(ii), Cd(ii) and Pb(ii) complexation with pyridinecarboxylate containing ligands. | Q46304800 |
| | Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies | Q46362578 |
| | Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies | Q46569961 |
| | "Click-to-chelate": design and incorporation of triazole-containing metal-chelating systems into biomolecules of diagnostic and therapeutic interest | Q46584205 |
| | Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies | Q36881146 |
| | Methodology for labeling proteins and peptides with lead-212 (212Pb) | Q36881360 |
| | 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint | Q36896084 |
| | A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies | Q36908712 |
| | Immuno-PET: a navigator in monoclonal antibody development and applications. | Q37047713 |
| | 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals | Q37126389 |
| | In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. | Q37129823 |
| | H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu | Q37142624 |
| | 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors | Q37148669 |
| | A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. | Q37172093 |
| | H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy | Q37209655 |
| | (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity | Q37218456 |
| | Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates | Q37223898 |
| | Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation | Q37226124 |
| | Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH. | Q37364790 |
| | (S)-5-(p-nitrobenzyl)-PCTA, a promising bifunctional ligand with advantageous metal ion complexation kinetics | Q37395793 |
| | H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. | Q37412579 |
| | Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. | Q37460994 |
| | Efficient bifunctional gallium-68 chelators for positron emission tomography: tris(hydroxypyridinone) ligands | Q37594420 |
| | Efficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticals | Q37722948 |
| | Iodine-124: a promising positron emitter for organic PET chemistry | Q37739199 |
| | Radiometallated peptides for molecular imaging and targeted therapy. | Q37847064 |
| | Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? | Q37864161 |
| | Theranostics: combining imaging and therapy | Q37914847 |
| | Radiometals for combined imaging and therapy | Q38063924 |
| | Tumour targeting with radiometals for diagnosis and therapy | Q38100112 |
| | A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. | Q39147376 |
| | [⁶⁸Ga]NS₃-RGD and [⁶⁸Ga] Oxo-DO3A-RGD for imaging α(v)β₃ integrin expression: synthesis, evaluation, and comparison. | Q39252884 |
| | (68)Ga small peptide imaging: comparison of NOTA and PCTA. | Q39266092 |
| | A monoreactive bifunctional triazacyclononane phosphinate chelator with high selectivity for gallium-68. | Q39332186 |
| | Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin. | Q39352243 |
| | RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga | Q39387478 |
| | Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging | Q39461465 |
| | Synthesis and evaluation of a series of 1,2,4,5-tetrazines for bioorthogonal conjugation | Q39467640 |
| | Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis | Q39505469 |
| P433 | issue | 1 | |
| P304 | page(s) | 260-290 | |
| P577 | publication date | 2013-10-30 | |
| P1433 | published in | Chemical Society Reviews | Q2962268 |
| P1476 | title | Matching chelators to radiometals for radiopharmaceuticals | |
| P478 | volume | 43 | |